• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    53 Biggest Movers From Yesterday

    3/30/22 3:33:05 AM ET
    $ALLG
    $AUUD
    $AVAH
    $BHIL
    Automotive Aftermarket
    Consumer Discretionary
    EDP Services
    Technology
    Get the next $ALLG alert in real time by email

    Gainers

    • IGM Biosciences, Inc. (NASDAQ:IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ:SNY) and IGM Biosciences signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against three oncology targets and three immunology/inflammation targets.
    • PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) jumped 46.1% to close at $1.68.
    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) climbed 45.4% to close at $0.2937 on Tuesday after declining 9% on Monday.
    • Oblong Inc. (NASDAQ:OBLG) jumped 45% to close at $0.8410. Oblong posted Q4 net loss of $2.71 million.
    • Clever Leaves Holdings Inc. (NASDAQ:CLVR) gained 40.3% to settle at $2.68.
    • MicroVision, Inc. (NASDAQ:MVIS) climbed 32.8% to close at $5.55. Microvision was granted US patent 'Alteration of resonant mode frequency response in mechanically resonant device.'
    • ECMOHO Limited (NASDAQ:MOHO) gained 28% to settle at $0.32.
    • Dave Inc. (NASDAQ:DAVE) climbed 27.5% to close at $8.31.
    • LianBio (NASDAQ:LIAN) gained 27.5% to settle at $3.57.
    • Kinnate Biopharma Inc. (NASDAQ:KNTE) surged 25.9% to close at $13.06. Kinnate Biopharma posted FY loss of $2.06 per share.
    • ShiftPixy, Inc. (NASDAQ:PIXY) gained 25.6% to settle at $0.8399.
    • Blackboxstocks Inc. (NASDAQ:BLBX) gained 25.6% to close at $2.45.
    • Randolph Bancorp, Inc. (NASDAQ:RNDB) rose 25.4% to close at $26.44 after Hometown Financial Group announced plans to acquire Randolph Bancorp for $27 per share in cash.
    • Robinhood Markets, Inc. (NASDAQ:HOOD) climbed 24.2% to settle at $15.91. Robinhood Markets on Tuesday unveiled extended trading hours for its brokerage platform, building on the company's aim to make investing more accessible for all.
    • Auddia Inc. (NASDAQ:AUUD) gained 23.2% to close at $2.28.
    • Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) rose 22.7% to close at $4.59 after the company reported better-than-expected Q4 sales results and issued FY22 sales guidance above analyst estimates.
    • Electric Last Mile Solutions, Inc. (NASDAQ:ELMS) jumped 22.5% to settle at $1.58.
    • NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) surged 22% to close at $4.66.
    • Molecular Templates, Inc. (NASDAQ:MTEM) gained 21.1% to close at $3.27 as the company posted a narrower quarterly loss.
    • The Lovesac Company (NASDAQ:LOVE) shares gained 20.8% to close at $56.99. Lovesac reported fourth-quarter FY22 sales growth of 51.3% year-on-year, to $196.2 million, beating the consensus of $174.33 million.
    • Grid Dynamics Holdings, Inc. (NASDAQ:GDYN) rose 20.5% to close at $14.26.
    • Nielsen Holdings plc (NYSE:NLSN) gained 20.3% to close at $26.72 after the company announced it will be acquire by a private equity consortium led by Evergreen Coast Capital and Brookfield Business Partners for $28 per share.
    • Team, Inc. (NYSE:TISI) jumped 19.4% to settle at $1.91.
    • Viracta Therapeutics, Inc. (NASDAQ:VIRX) gained 18.4% to close at $4.75.
    • Guardforce AI Co., Limited (NASDAQ:GFAI) climbed 17.8% to close at $1.39 after the company announced it is in the process of establishing subsidiaries in Dubai and Australia, with a focus on Robotics as a Service rollout initiatives.
    • Genenta Science S.p.A. (NASDAQ:GNTA) gained 16.8% to close at $7.30.
    • Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) rose 16.3% to settle at $12.68. Monte Rosa Therapeutics reported a Q4 net loss of $23.4 million.
    • TRxADE HEALTH, Inc. (NASDAQ:MEDS) gained 14.4% to close at $2.62 after the company reported Q4 earnings results.
    • Gelesis Holdings, Inc. (NYSE:GLS) rose 13% to close at $5.49. Gelesis Holdings recently reported FY EPS of $85.22.
    • Hycroft Mining Holding Corporation (NASDAQ:HYMC) shares climbed 11.6% to close at $2.59 after jumping 80% on Monday.
    • NexImmune, Inc. (NASDAQ:NEXI) rose 8.6% to close at $3.52 after declining 24% on Monday.
    • Nautilus, Inc. (NYSE:NLS) gained 8.3% to close at $4.31.

     

    Losers

    • NeoGenomics, Inc. (NASDAQ:NEO) shares tumbled 29.8% to close at $12.49 on Tuesday after the company announced it expects Q1 sales to be below its previously issued guidance range and withdrew its FY22 guidance. The company also announced Mark Mallon has agreed to step down as CEO.
    • Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) fell 26.7% to close at $3.95 after the company said FY21 EPS results were down from last year. The company also issued FY22 sales guidance below analyst estimates. B of A Securities downgraded the stock from Buy to Neutral and lowered the price target from $10 to $5.5.
    • Stryve Foods, Inc. (NASDAQ:SNAX) shares dipped 24.8% to close at $1.50 after reporting weak quarterly sales.
    • Progenity, Inc. (NASDAQ:PROG) fell 23% to close at $1.24 after reporting Q4 results.
    • Soleno Therapeutics, Inc. (NASDAQ:SLNO) fell 22.8% to close at $0.2220 after the company announced pricing of a roughly $15 million underwritten public offering.
    • Lipocine Inc. (NASDAQ:LPCN) shares dipped 20.3% to close at $1.45. Antares Pharma announced the FDA granted final approval for oral testosterone replacement therapy Tlando for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males. Tlando was developed by Lipocine, with the company exclusively out-licensing the U.S. commercialization rights to Antares.
    • Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) dropped 19.6% to close at $3.65.
    • Uxin Limited (NASDAQ:UXIN) fell 18.8% to close at $1.21 after the company reported Q3 financial results.
    • Terran Orbital Corporation (NYSE:LLAP) fell 16.4% to close at $9.86.
    • Benson Hill, Inc. (NYSE:BHIL) fell 16.3% to close at $3.35. Barclays maintained Benson Hill with an Overweight and lowered the price target from $10 to $8.
    • Ocuphire Pharma, Inc. (NASDAQ:OCUP) fell 16.2% to close at $3.56 after the company reported topline results from MIRA-3 Phase 3 FDA registration trial for Nyxol® in the reversal of mydriasis.
    • Marin Software Incorporated (NASDAQ:MRIN) fell 15% to close at $3.12 after jumping over 35% on Monday.
    • FGI Industries Ltd. (NASDAQ:FGI) fell 14.8% to close at $3.10 following Q4 results.
    • ThermoGenesis Holdings, Inc. (NASDAQ:THMO) dipped 14.7% to settle at $0.6501 the company reported FY21 sales results were down from last year.
    • Allego N.V. (NYSE:ALLG) fell 14.4% to close at $17.90.
    • Kala Pharmaceuticals, Inc. (NASDAQ:KALA) fell 14.3% to settle at $1.50 following Q4 results.
    • SCYNEXIS, Inc. (NASDAQ:SCYX) dipped 13% to close at $4.09 following Q4 results.
    • Kaixin Auto Holdings (NASDAQ:KXIN) fell 13% to close at $1.27. Kaixin shares jumped over 31% on Monday after the company announced an order for 20,000 electric vehicles.
    • Revelation Biosciences, Inc. (NASDAQ:REVB) dipped 9.3% to close at $2.14.
    • Conn's, Inc. (NASDAQ:CONN) fell 7.1% to settle at $18.96 following Q4 results.
    • Save Foods, Inc. (NASDAQ:SVFD) fell 6.7% to settle at $5.72.
    Get the next $ALLG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLG
    $AUUD
    $AVAH
    $BHIL

    CompanyDatePrice TargetRatingAnalyst
    Sanofi
    $SNY
    1/27/2026Neutral
    Citigroup
    Sanofi
    $SNY
    1/16/2026Buy → Neutral
    UBS
    Robinhood Markets Inc.
    $HOOD
    1/9/2026$145.00Buy
    Argus
    Sanofi
    $SNY
    1/6/2026Overweight → Equal Weight
    Barclays
    Robinhood Markets Inc.
    $HOOD
    12/29/2025$145.00 → $135.00Buy
    Needham
    Robinhood Markets Inc.
    $HOOD
    12/17/2025$155.00Buy
    Truist
    Sanofi
    $SNY
    12/9/2025Buy → Neutral
    Guggenheim
    Aveanna Healthcare Holdings Inc.
    $AVAH
    12/8/2025Outperform
    William Blair
    More analyst ratings

    $ALLG
    $AUUD
    $AVAH
    $BHIL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sprott Eric bought $9,198,000 worth of shares (200,000 units at $45.99) (SEC Form 4)

    4 - HYCROFT MINING HOLDING CORP (0001718405) (Issuer)

    1/30/26 8:35:50 PM ET
    $HYMC
    Precious Metals
    Basic Materials

    Large owner Sprott Eric bought $4,996,000 worth of shares (100,000 units at $49.96) (SEC Form 4)

    4 - HYCROFT MINING HOLDING CORP (0001718405) (Issuer)

    1/27/26 9:16:28 PM ET
    $HYMC
    Precious Metals
    Basic Materials

    Large owner Sprott Eric exercised 4,672,352 shares at a strike of $6.00 and bought $6,642,000 worth of shares (200,000 units at $33.21) (SEC Form 4)

    4 - HYCROFT MINING HOLDING CORP (0001718405) (Issuer)

    1/15/26 8:04:28 PM ET
    $HYMC
    Precious Metals
    Basic Materials

    $ALLG
    $AUUD
    $AVAH
    $BHIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Sanofi

    Citigroup initiated coverage of Sanofi with a rating of Neutral

    1/27/26 8:49:24 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi downgraded by UBS

    UBS downgraded Sanofi from Buy to Neutral

    1/16/26 8:32:26 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Argus initiated coverage on Robinhood Markets with a new price target

    Argus initiated coverage of Robinhood Markets with a rating of Buy and set a new price target of $145.00

    1/9/26 8:12:05 AM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance

    $ALLG
    $AUUD
    $AVAH
    $BHIL
    SEC Filings

    View All

    SEC Form PRE 14A filed by Revelation Biosciences Inc.

    PRE 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/6/26 4:32:19 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    2/6/26 10:09:38 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hycroft Mining Holding Corporation filed SEC Form 8-K: Leadership Update, Shareholder Director Nominations, Other Events

    8-K - HYCROFT MINING HOLDING CORP (0001718405) (Filer)

    2/6/26 9:00:41 AM ET
    $HYMC
    Precious Metals
    Basic Materials

    $ALLG
    $AUUD
    $AVAH
    $BHIL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dave Reports Preliminary Fourth Quarter and Full Year 2025 Results

    2025 Revenue and Adjusted EBITDA Results are Expected to Exceed the Top-End of Guidance 4Q25 28 DPD Rate Expected to be Within the Range of 1.95%-2.00%, Outperforming Guidance of Below 2.10% Full Earnings Results and 2026 Financial Outlook to Be Discussed on March 2, 2026 at 5:00pm ET LOS ANGELES, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced certain preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company expects to release full, audited financial results and file its annual report on Form 10-K for the year ended December 31, 2025 on Mar

    2/5/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark

    Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratoryPreprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesisGPT-5-driven autonomous lab executed over 36,000 experimentsGinkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven scienceBOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free p

    2/5/26 2:00:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Grid Dynamics to Announce Fourth Quarter and Full Year 2025 Financial Results on March 5th

    Grid Dynamics Holdings, Inc. (NASDAQ:GDYN) ("Grid Dynamics"), a leader in enterprise-level digital transformation services and solutions, today announced that it will host a video conference call at 4:30 p.m. ET on Thursday, March 5, 2026 to discuss its fourth quarter and full year 2025 financial results. A press release containing these results will be available on our website prior to the call. A webcast of the video conference call, as well as a replay available after the event, can be accessed on the Investor Relations section of the company's website at https://www.griddynamics.com/investors. About Grid Dynamics Grid Dynamics (NASDAQ:GDYN) is a leading provider of technology cons

    2/5/26 9:15:00 AM ET
    $GDYN
    Computer Software: Prepackaged Software
    Technology

    $ALLG
    $AUUD
    $AVAH
    $BHIL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    11/4/24 4:49:34 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLG
    $AUUD
    $AVAH
    $BHIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heyer Andrew R was granted 279 shares, increasing direct ownership by 0.11% to 250,643 units (SEC Form 4)

    4 - Lovesac Co (0001701758) (Issuer)

    2/5/26 5:55:11 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    Director Roper Jess covered exercise/tax liability with 1,591 shares, decreasing direct ownership by 11% to 12,828 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/5/26 5:31:20 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chawla Lakhmir S covered exercise/tax liability with 2,261 shares, decreasing direct ownership by 16% to 12,158 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/5/26 5:30:45 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLG
    $AUUD
    $AVAH
    $BHIL
    Financials

    Live finance-specific insights

    View All

    Dave Reports Preliminary Fourth Quarter and Full Year 2025 Results

    2025 Revenue and Adjusted EBITDA Results are Expected to Exceed the Top-End of Guidance 4Q25 28 DPD Rate Expected to be Within the Range of 1.95%-2.00%, Outperforming Guidance of Below 2.10% Full Earnings Results and 2026 Financial Outlook to Be Discussed on March 2, 2026 at 5:00pm ET LOS ANGELES, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced certain preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company expects to release full, audited financial results and file its annual report on Form 10-K for the year ended December 31, 2025 on Mar

    2/5/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Grid Dynamics to Announce Fourth Quarter and Full Year 2025 Financial Results on March 5th

    Grid Dynamics Holdings, Inc. (NASDAQ:GDYN) ("Grid Dynamics"), a leader in enterprise-level digital transformation services and solutions, today announced that it will host a video conference call at 4:30 p.m. ET on Thursday, March 5, 2026 to discuss its fourth quarter and full year 2025 financial results. A press release containing these results will be available on our website prior to the call. A webcast of the video conference call, as well as a replay available after the event, can be accessed on the Investor Relations section of the company's website at https://www.griddynamics.com/investors. About Grid Dynamics Grid Dynamics (NASDAQ:GDYN) is a leading provider of technology cons

    2/5/26 9:15:00 AM ET
    $GDYN
    Computer Software: Prepackaged Software
    Technology

    NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 5

    1/27/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $ALLG
    $AUUD
    $AVAH
    $BHIL
    Leadership Updates

    Live Leadership Updates

    View All

    Team, Inc. Announces Planned Leadership Transition and Names Gary Hill as Chief Executive Officer

    SUGAR LAND, Texas, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE:TISI) ("TEAM" or the "Company"), a leading provider of specialty industrial services offering a full suite of mechanical, heat-treating, and inspection services around the world, today announced that Keith Tucker will retire from Team after over 20 years of service. In conjunction with this planned leadership transition, TEAM's Board of Directors has appointed Gary Hill as the Company's Chief Executive Officer effective February 1, 2026 to lead the Company in its continued focus on driving accelerated growth and margin improvements. The Company also reaffirms its previously issued 2025 outlook. "On behalf of the Board o

    1/26/26 5:00:00 PM ET
    $TISI
    Other Consumer Services
    Consumer Discretionary

    Dave Inc. Appoints Nima Khajehnouri to Board of Directors; Announces Board Leadership Transitions

    LOS ANGELES, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced that Nima Khajehnouri, a distinguished leader in artificial intelligence and data engineering, has joined its Board of Directors, effective immediately. Mr. Khajehnouri will serve as a member of the Company's Audit Committee. Imran Khan, who has served on the Board since August 2023, is stepping down in conjunction with this appointment. Mr. Khajehnouri brings more than two decades' experience of leading engineering at some of the world's most influential technology companies. He currently serves as Vice President of Engineering at Meta, h

    1/20/26 5:27:46 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

    – Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, Neo

    1/12/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $ALLG
    $AUUD
    $AVAH
    $BHIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NeuroSense Therapeutics Ltd.

    SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

    12/9/24 4:00:18 PM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/18/24 9:49:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care